A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Inclusion Criteria:

• Confirmed evidence of atherosclerosis

• Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan

• Stable treatment of atherosclerosis through the use of SOC medications orrevascularization

• QT interval corrected through use of Fridericia's formula (QTcF) of ≤ 450milliseconds (ms) in men and ≤ 470 ms in women by a single 12-lead electrocardiogram (ECG) recording

Exclusion Criteria:

• Individuals with Class III and IV heart failure

• Uncontrolled cardiac arrhythmia

• Uncontrolled hypertension

• Suspected or known immunocompromised state

• Planned procedure or surgery during the study and any major surgery within 90 daysprior to screening Visit 1

• History of malignancy within 5 years prior to screening, except for appropriatelytreated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage Iuterine cancer

• Positive test results for hepatitis B (HBV) infection at screening

• Positive hepatitis C virus (HCV) antibody test at screening

• Positive human immunodeficiency virus (HIV) test at screening

• Treatment with any live vaccine within 28 days prior to the first dose of study druguntil the end of the study

• Treatment with other non-live vaccines within 14 days prior to the first dose ofstudy drug until the end of the study